Navigation Links
Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
Date:8/26/2008

matic corresponding increase in market capitalization of nearly 200%. The Company believes, however, that its valuation remains well below the market capitalization and corresponding share price of above $3.00 per share. We further believe that our share price has been impacted by the overall decline in the Chinese capital markets.

"We have therefore retained CB Capital Partners as our financial advisor to assist in reviewing our strategic alternatives with the objective of maximizing shareholder value, and we look forward to working with them to ensure that all alternatives available to the Company are considered and evaluated to achieve that objective."

These alternatives may range from strategic alliances to assist in the development of its pipeline drugs to financing opportunities such as mergers, acquisitions, a sale of all or part of the business, or other initiatives considered to be in the best interests of the Company and its shareholders.

ABOUT CB CAPITAL PARTNERS

CB Capital Partners is a specialized investment banking firm, which focuses on creating value through customized financial advisory assignments including capital raises, debt placements, strategic and financial partnerships, and mergers and acquisitions transactions. The firm was founded in 2001 in order to bring innovative and value-added solutions to our clientele through a conservative and disciplined application of our diverse professional institutional investment banking talents. http://www.cbcapital.com

ABOUT SINOBIOMED, INC.

Sinobiomed, Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials and three in research and development. The Company's products respond to a wide range of diseases and conditions, including: malaria, h
'/>"/>

SOURCE Sinobiomed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Yongye Biotechnology International Retains CCG Investor Relations
2. Shengtai Pharmaceutical Retains Grayling Global As Investor Relations Counsel
3. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
4. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
5. CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing
6. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
7. SPO Medical Retains American Capital Ventures for Investor Relations Services
8. Interleukin Genetics Retains Top Life Science Communications Firms
9. Dragon retains leading investor relations firm
10. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
11. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its first quarter 2015 financial results ... before the open of market. At 8:30 am Eastern ... to discuss the financial results and provide a ...
(Date:5/1/2015)... , May 1, 2015 ... market for antithrombotic drugs will reach $22.4bn in 2019. ... Drugs: World Industry and Market Prospects 2015-2025 ... of that investigation is to provide forecasts and qualitative ... business information publisher and consultancy in London, ...
(Date:5/1/2015)... Albany Molecular Research Inc. (NASDAQ: AMRI ... AMRI,s President and Chief Executive Officer, will present at ... Conference on Wednesday, May 13, 2015 at 4:20 p.m. ... presentation can be accessed at AMRI,s Investor Relations web ... will be archived for 90 days following the live ...
(Date:5/1/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE ... Corporation (NASDAQ: UTHR ) announced today that Roger ... Therapeutics, will provide an overview and update on the company,s ... Care Conference in Boston, Massachusetts . ... 2015, at 3:30 PM Eastern Time, and can be accessed ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2
... presentation Sunday, May 17, 8:15 a.m. PDT - - ... p.m. PDT - - Conference call and webcast Tuesday, ... 14 InterMune, Inc. (Nasdaq: ITMN ) today ... presentations related to the company,s pulmonology programs will be presented ...
... substantially increased capacity, for continued growth,TORONTO, ... today robust double digit growth in sales, improved cash ... ended March 31, 2009. , In a news release ... 43% growth in the first half of 2009 coupled ...
... Dendreon Corporation today announced that Chief Executive Officer, ... Ernst & Young Entrepreneur Of The Year (R) ... Ernst & Young LLP, the awards program recognizes entrepreneurs ... financial performance and personal commitment to their businesses and ...
Cached Biology Technology:Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 3Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 4Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest 2
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... TALLAHASSEE, Fla. -- Reductions in the flow of the ... to grouper and other reef fish populations in the ... State University study that may provide new ammunition for ... The Florida State researchers found that in years with ...
... The SIB Swiss Institute of Bioinformatics today announced the winners ... Young Bioinformatician Award at the 7th annual [BC]2 Basel Computational ... , The winner of the 2009 SIB Young Bioinformatician ... working for the past four years with the SIB in ...
... Discovered Interferon Response May Offer Early Control of H5N1 Influenza ... protein, interferon type 1, reduced H5N1 influenza virus replication in ... early stages of infection. They report their findings in ... . Highly pathogenic avian influenza H5N1 ...
Cached Biology News:Troubled waters: Low Apalachicola River flow may hurt gulf fisheries 2Troubled waters: Low Apalachicola River flow may hurt gulf fisheries 3The SIB recognizes the next generation of bioinformaticians 2The SIB recognizes the next generation of bioinformaticians 3Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4
... the DH-2000, but comes with a shutter (controlled ... 5 Hz) The DH-2000 Deuterium ... of deuterium and tungsten halogen light sources in ... produces a powerful, stable output from 215-200 nm. ...
... The MSD Security ChemStation ... GC/MS software application for ... quantification, library searching and ... aspects of data security, ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... Nematode microRNA Microarray contains all known ...
... critical to the maintenance of appropriate ... as important and diverse as those ... and stress response, antigen presentation, modulation ... channels, cell cycle regulation, transcription, and ...
Biology Products: